Literature DB >> 4037187

Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys.

J V Lange, S W Mitchell, J B McCormick, D H Walker, B L Evatt, R R Ramsey.   

Abstract

The rhesus monkey, an established model of Lassa fever, was used to study hematologic and hemostatic aspects of Lassa fever and whether Mopeia (also known as Mozambique) virus induces any cellular damage in this model. Six days after subcutaneous injection of 10(3.48) plaque forming units (PFU) of Lassa virus (Josiah strain) one group of monkeys received an intravenous injection of 111In-labeled allogeneic platelets and another group received 125I-labeled alogeneic fibrinogen. Lassa virus-infected monkeys developed a severe clinical illness with high viremia and typical pathology. Lassa antigen was found in most tissues using a Lassa nucleocapsid-specific monoclonal antibody. Platelet counts remained within normal limits. Platelet and fibrinogen kinetics were similar in infected and control animals. Hematologic and hemostatic changes indicate that disseminated intravascular coagulation plays no role in this model of Lassa fever. Levels of plasma fibronectin were reduced in Lassa-infected monkeys. Mopeia virus-infected monkeys were normothemic, aviremic, and there was no detection of Mopeia antigen in any tissues using polyclonal or monoclonal antibodies. Mopeia virus was recovered from the spleen of one monkey. Mopeia virus was associated with hepatocellular and renal tubular damage.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4037187     DOI: 10.4269/ajtmh.1985.34.999

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

1.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

2.  A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques.

Authors:  David Safronetz; James E Strong; Friederike Feldmann; Elaine Haddock; Nafomon Sogoba; Douglas Brining; Thomas W Geisbert; Dana P Scott; Heinz Feldmann
Journal:  J Infect Dis       Date:  2013-01-09       Impact factor: 5.226

3.  Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Authors:  Sylvain Baize; Philippe Marianneau; Philippe Loth; Stéphanie Reynard; Alexandra Journeaux; Michèle Chevallier; Noël Tordo; Vincent Deubel; Hugues Contamin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

4.  Pathogenesis of Lassa fever in cynomolgus macaques.

Authors:  Lisa E Hensley; Mark A Smith; Joan B Geisbert; Elizabeth A Fritz; Kathleen M Daddario-DiCaprio; Tom Larsen; Thomas W Geisbert
Journal:  Virol J       Date:  2011-05-06       Impact factor: 4.099

Review 5.  Human hemorrhagic Fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis.

Authors:  Junjie Shao; Yuying Liang; Hinh Ly
Journal:  Pathogens       Date:  2015-05-21

Review 6.  Pathogenesis of Lassa fever.

Authors:  Nadezhda E Yun; David H Walker
Journal:  Viruses       Date:  2012-10-09       Impact factor: 5.048

Review 7.  Immune responses and Lassa virus infection.

Authors:  Marion Russier; Delphine Pannetier; Sylvain Baize
Journal:  Viruses       Date:  2012-11-05       Impact factor: 5.048

Review 8.  Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.

Authors:  Stephan Olschläger; Lukas Flatz
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

Review 9.  Advanced vaccine candidates for Lassa fever.

Authors:  Igor S Lukashevich
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

Review 10.  Animal models, prophylaxis, and therapeutics for arenavirus infections.

Authors:  Eric Vela
Journal:  Viruses       Date:  2012-09-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.